Immunogenicity of hepatitis a vaccine in children with cancer.
This study evaluated the immuned response of the hepatitis A vaccine in children with cancer who were receiving chemotherapy. Twenty-eight patients with lymphomas or solid tumors and who had negative serology for hepatitis A were enrolled. The median age was 4.7 years (range 2-16). The patients received 1440 IU hepatitis A vaccine at 0 and 6 months. Seroconversion rates at the first and seventh months were 60% (n = 17/28 patients) and 89% (n = 24/27 patients). No adverse effects were observed. The hepatitis A vaccine was found to be effective and safe in children with cancer.
Köksal
Yavuz
Y
Department of Pediatric Oncology, Hacettepe University, Institute of Oncology, 06100, Ankara, Turkey. yavuzkoksal@yahoo.com
Yalçin
Bilgehan
B
Aydin
G Burça
GB
Sari
Neriman
N
Yazici
Nalan
N
Varan
Ali
A
Kutluk
Tezer
T
Akyüz
Canan
C
Büyükpamukçu
Münevver
M
D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D005260:Female; D005500:Follow-Up Studies; D035922:Hepatitis A Antibodies / Q000096:biosynthesis / Q000097:blood*; D022362:Hepatitis A Vaccines / Q000276:immunology*; D006801:Humans; D007074:Immunoglobulin G / Q000096:biosynthesis / Q000097:blood; D007075:Immunoglobulin M / Q000096:biosynthesis / Q000097:blood; D008297:Male; D009369:Neoplasms / Q000276:immunology*; D011446:Prospective Studies
D035922:Hepatitis A Antibodies; D022362:Hepatitis A Vaccines; D007074:Immunoglobulin G; D007075:Immunoglobulin M